Last checked at 25 Oct 2023 17:53
25 October 2023
Feedback plc
Director/PDMR Dealing
Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialist, was informed on 24 October 2023 that on 7 September 2023, 5,422 ordinary shares of 50 pence each in capital of the Company ("Ordinary Shares") held by Annemijn Eschauzier, Non-Executive Director of the Company, were inadvertently sold at a price of 87.1 pence per Ordinary Share. This sale was made inadvertently due to a clerical error by the administrator of Annemijn Eschauzier's investment account during a transition of Annemijn Eschauzier's wider investment portfolio. Annemijn Eschauzier did not provide instruction for this sale to take place. Annemijn Eschauzier intends to repurchase the 5,422 Ordinary Shares.
Following this sale of Ordinary Shares, Annemijn Eschauzier holds an interest in 18 Ordinary Shares in the Company, representing 0.00% of the Company's issued share capital.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1
| Details of the person discharging managerial responsibilities / person closely associated | ||||
a)
| Names | Annemijn Eschauzier
| |||
2
| Reason for the notification | ||||
a)
| Position/status
| Non-Executive Director | |||
b)
| Initial notification /Amendment | Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a)
| Name | Feedback plc | |||
b)
| LEI
| 213800UGOF2GT2U2RV90 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of 50 pence each in Feedback plc | |||
Identification code | GB00BJN59X09 | ||||
b)
| Nature of the transaction | Sale of Ordinary Shares | |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
87.1 pence | 5,422 | ||||
d)
| Aggregated information | ||||
- Aggregated volume | n/a | ||||
- Price | |||||
e)
| Date of the transaction | 7 September 2023 | |||
f)
| Place of the transaction | XLON | |||
- Ends -
Enquiries:
Feedback plc Tom Oakley, CEO Anesh Patel, CFO | +44 (0) 20 3997 7634 IR@fbk.com |
| |
Panmure Gordon (UK) Limited (NOMAD and Broker) Emma Earl/Freddy Crossley (Corporate Finance) Rupert Dearden (Corporate Broking) | +44 (0)20 7886 2500 |
| |
Walbrook PR Ltd; | Tel: 020 7933 8780 or feedbackplc@walbrookpr.com |
Nick Rome/Joe Walker | 07748 325 236 or 07407 020 470 |
About Feedback
Feedback plc helps clinical teams to make better decisions faster for patients. We design products that enhance clinician access to patient data and to their colleagues. Our unique approach centres around individual patient episodes, into which we pull relevant clinical data from hospital systems and around which we build remote clinical teams for collaboration. As a result, we produce a digital infrastructure that makes patient data available to clinicians in multiple settings, in a format that enables them to meaningfully interact with it, providing flexibility to clinicians and free movement of patients between provider settings - clinicians can practice from anywhere and patients can attend any care provider for treatment.
Our products Bleepa and CareLocker work together to deliver unparalleled value to our customers. Bleepa is our application layer and sits on top of CareLocker as our data layer. Bleepa is a clinician facing platform that displays clinical results from a patient's CareLocker at a certified and regulated quality, that is suitable for clinical use and enables dialogue on a patient-by-patient basis with colleagues through a secure, auditable chat interface that links back to the patient medical record. The CareLocker data storage model is built around the patient. Our vision is one where relevant clinical data is always available to the patient as well as to any care setting that they may attend - a federated data architecture with the patient as the tenant.
The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.